PHARMA BASE
ActiveSummary
The computed 12-month bankruptcy probability of PHARMA BASE is 3.5% (moderate). The 2024 annual accounts show equity of €2.5m and a net result of €178,876. Equity remains stable across the filed financial years (±2.4% per year). Its solvency ranks better than 16% of 6,064 sector peers (NACE 46, financial year 2024). The company has been active since 1990 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
Wholesale of pharmaceutical and medical goods
NACE 46460Retail sale of pharmaceutical products NACE 47730
Fastest staff growth in Genk, Wholesale and retail trade sector3 sites
Size
€75.2mturnover 2024
- Staff
- 29 FTE
- Equity
- €2.5m
- Profit
- €178,876
Structure
- Parent
- peeters mathieu management · 100%
- PEETERS MATHIEU MANAGEMENTDirector
Auditor: RSM INTERAUDIT2025 accounts not filed, 89 days past the deadline2 of 21 deeds summarised
Why 49raises riskFigures for financial year 2024 (filed 26-06-2025)Liquidity: current ratio 1.11, cash €645,070, halvedEquity €2.5m (12.0% of total assets)Size: turnover €75.2m, 29 FTE, total assets €21.1mShow the evidence
Checked score
Score 2024
49
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 31% of its sector peers (NACE 46, small)
Financial strength · tick = 2023
Weak
Solvency
37=
equity 12.0% of total assets
Liquidity
5-8
short-term debt 87.8% · cash 3.1%
Profitability
43=
return on assets 0.8%
Bankruptcy probability, 12 months
3.5%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.4%
12-2024: 0.4%● unchanged vs 11-2024
01-2025: 0.4%● unchanged vs 12-2024
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025lowest value
07-2025: 0.9%▲ +0.5 percentage points vs 06-2025
08-2025: 0.9%● unchanged vs 07-2025
09-2025: 0.9%● unchanged vs 08-2025
10-2025: 0.9%● unchanged vs 09-2025
11-2025: 0.9%● unchanged vs 10-2025
12-2025: 0.9%● unchanged vs 11-2025
01-2026: 0.9%● unchanged vs 12-2025
02-2026: 0.9%● unchanged vs 01-2026
03-2026: 0.9%● unchanged vs 02-2026
04-2026: 0.9%● unchanged vs 03-2026
05-2026: 0.9%● unchanged vs 04-2026
06-2026: 0.9%● unchanged vs 05-2026
07-2026: 1.0%▲ +0.1 percentage points vs 06-2026
08-2026: 1.7%▲ +0.7 percentage points vs 07-2026
09-2026: 2.2%▲ +0.5 percentage points vs 08-2026
10-2026: 3.5%▲ +1.3 percentage points vs 09-2026highest value
Credit of up to €120,000 on 30-day terms, only on tighter conditions: an expected filing is missing beyond Checked's processing allowance
Liquidity tight (current ratio 1.11, compared with 1.11 in 2023, below the usual 1.5; short-term debt: 87.8% and cash: 3.1% of total assets), and 88% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 14% on solvency, 5% on liquidity, 28% on profitability and 77% on growth.
The bankruptcy probability was computed on 27-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Seven signals.
raises riskneutral
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 16% of 6064 sector peers (2024).
NBB · sector comparisonPosition among 6064 sector peers
Solvency
better than 16%
← weakest
strongest →
raises risk · Annual accounts not filed
The financial year that closed on 31-12-2025 was due at the National Bank by 31-07-2026. Nothing is on record, 89 days later.
NBB · 10 filingsPosition against the passed deadline
31-12-2025 year end31-07-2026 deadline28-10-2026 today
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not filed
2024
38 days early
2023
on the day
2022
20 days early
2021
39 days early
2020
37 days early
2019
15 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 25 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (1)
- Annual accounts filedfinancial year 2024 · full…
- Annual accounts filedfinancial year 2023 · full…
- Resignations: PHARMA FORCE (director) and BXI…Permanent representatives: PEETERS Mathieu and…
Financials · financial year 2024, full format
In the rankings
#1 company by staff growth in Genk, Wholesale and retail trade sector#7 company by total assets in Genk, Wholesale and retail trade sector
2025 annual accounts not yet filed, deadline passed on 31 July 2026 Financial year closed on 31 December 2025; filing due at the latest 7 months after the close (Companies Code art. 3:10). Source: NBB filings, as of 28 October 2026.
Turnover
€75.2m▲ 25.1%
2023 · €60.2m
EBIT margin
0.5%▲ 0.1pp
2023 · 0.4%
Net result
€178,876▲ 328%
2023 · €41,833
Working capital
€2.0m▲ 9.1%
2023 · €1.8m
Trend over the years
2020 to 2024, 5 financial years 2018 to 2024, 7 financial years
The operating result recovers in 2024; 2024 is 51% above 2023.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Turnover€75.2m
2024
Operating result€0.4m
2024
Net result€0.2m
2024
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€21.1m
2024
Equity€2.5m
2024
Debt€18.5m
2024
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€2.0m
2024
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
EBIT margin0.5%
2024
Return on assets (ROA)0.8%
2024
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency12.0%
2024
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio1.11
2024
Average staff in full-time equivalents (FTE).
Staff (FTE)29
2024
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line2018201920202021202220232024
Turnover€32.8m-€46.4m▲ 41.4%€56.8m▲ 22.4%€56.2m▼ 1.0%€52.1m▼ 7.2%€60.2m▲ 15.4%€75.2m▲ 25.1%
Operating result€2.2m-€1.0m▼ 53.8%€0.5m▼ 51.3%€0.7m▲ 30.1%€0.3m▼ 53.8%€0.2m▼ 19.9%€0.4m▲ 51.3%
Net result€0.9m-€0.7m▼ 28.0%€0.3mwithin the sector's middle half▼ 51.5%€0.5mwithin the sector's middle half▲ 48.4%€0.1mwithin the sector's middle half▼ 69.7%€0.04mwithin the sector's middle half▼ 71.6%€0.2mwithin the sector's middle half▲ 328%
EBIT margin6.8%-2.2%▼ 4.6pp0.9%▼ 1.3pp1.2%▲ 0.3pp0.6%▼ 0.6pp0.4%▼ 0.2pp0.5%▲ 0.1pp
Equity€2.7m-€3.3m▲ 25.2%€3.7mwithin the sector's middle half▲ 9.8%€4.2mwithin the sector's middle half▲ 13.2%€2.3mwithin the sector's middle half▼ 44.5%€2.3mwithin the sector's middle half▲ 1.8%€2.5mwithin the sector's middle half▲ 7.6%
Total assets€14.6m-€19.8m▲ 35.9%€18.3mabove the sector's middle half▼ 7.4%€17.5mabove the sector's middle half▼ 4.5%€19.9mabove the sector's middle half▲ 13.3%€19.1mabove the sector's middle half▼ 3.9%€21.1mabove the sector's middle half▲ 10.4%
Debt€11.9m-€16.5m▲ 38.4%€14.7m▼ 10.9%€13.4m▼ 8.9%€17.5m▲ 31.3%€16.7m▼ 4.6%€18.5m▲ 10.8%
Working capital€3.8m-€4.1m▲ 7.7%€4.0mabove the sector's middle half▼ 2.3%€4.2mabove the sector's middle half▲ 5.5%€2.1mwithin the sector's middle half▼ 49.1%€1.8mwithin the sector's middle half▼ 14.5%€2.0mwithin the sector's middle half▲ 9.1%
Solvency18.4%-16.9%▼ 1.4pp20.0%within the sector's middle half▲ 3.1pp23.7%within the sector's middle half▲ 3.7pp11.6%below the sector's middle half▼ 12.1pp12.3%below the sector's middle half▲ 0.7pp12.0%below the sector's middle half▼ 0.3pp
Current ratio1.35-1.26▼ 0.091.28within the sector's middle half▲ 0.021.32within the sector's middle half▲ 0.041.12below the sector's middle half▼ 0.201.11below the sector's middle half▼ 0.011.11below the sector's middle half=
Return on assets (ROA)6.4%-3.4%▼ 3.0pp1.8%within the sector's middle half▼ 1.6pp2.8%within the sector's middle half▲ 1.0pp0.7%below the sector's middle half▼ 2.0pp0.2%below the sector's middle half▼ 0.5pp0.8%within the sector's middle half▲ 0.6pp
Staff (FTE)8.8-11.6▲ 31.8%15.1within the sector's middle half▲ 30.2%17.3within the sector's middle half▲ 14.6%18.8within the sector's middle half▲ 8.7%23within the sector's middle half▲ 22.3%29within the sector's middle half▲ 26.1%
above
within
below
the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €21.1m
Fixed assets
€570,670 ▼ 1.0%
Current assets
€20.5m ▲ 10.7%
Equity and liabilities €21.1m
Equity
€2.5m ▲ 7.6%
Debt
€18.5m ▲ 10.8%
Debt's share of the balance-sheet total rises from 87.7% to 88.0%. Equity and debt are higher.
Key figures and ratios
EBITDA
€480,102▲
2023 · €349,310
Cash flow
€294,184▲
2023 · €150,043
Quick ratio
0.75▼
2023 · 0.83
Debt to equity
7.34▲
2023 · 7.13
ROE
7.1%▲
2023 · 1.8%
Interest coverage
3.95▼
2023 · 4.13
Debt ≤ 1 year
€18.5m▲
2023 · €16.7m
Debt > 1 year
€32,898▼
2023 · €49,960
Income taxes
€66,037▼
2023 · €116,004
Staff costs
€1.3m▲
2023 · €1.1m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 4,685 companies that looked in July 2024 the way this one looks now, 1.1% went bankrupt within 24 months and 96.9% are still going.
- Small
- 20 years or older
- solvency 10 to 30%
- a profit under 5% of the balance sheet
1.1%
went bankrupt
1.9%
stopped otherwise
96.9%
still going
For this company itself Checked computes a higher bankruptcy probability: 3.5% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 4,685 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | - | €56.2m | €52.2m | €60.2m | €75.4m | ▲ 25.3% |
| Turnover70 | €32.8m | €46.4m | €56.8m | €56.2m | €52.1m | €60.2m | €75.2m | ▲ 25.1% |
| Other operating income74 | - | - | - | €0.05m | €0.02m | €0.03m | €0.2m | ▲ 577% |
| Non-recurring operating income76A | - | - | - | - | - | €0.001m | €0.03m | ▲ 25× |
| Operating charges60/66A | - | - | - | €55.6m | €51.9m | €60.0m | €75.1m | ▲ 25.2% |
| Goods for resale, raw materials and consumables60 | - | - | - | €51.4m | €48.5m | €56.3m | €70.6m | ▲ 25.6% |
| Purchases600/8 | - | - | - | €51.2m | €49.1m | €56.8m | €72.6m | ▲ 27.8% |
| Change in stocks: decrease (increase)609 | - | - | - | €0.2m | -€0.6m | -€0.6m | -€2.0m | ▼ 257% |
| Services and other goods61 | - | - | - | €3.3m | €2.4m | €2.5m | €2.9m | ▲ 16.3% |
| Remuneration, social security and pensions62 | - | - | - | €0.7m | €0.8m | €1.1m | €1.3m | ▲ 24.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.09m | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | ▲ 6.6% |
| Other operating charges640/8 | - | - | - | €0.006m | €0.01m | €0.02m | €0.02m | ▼ 20.0% |
| Non-recurring operating charges66A | - | - | - | - | €0.009m | €0.007m | €0.09m | ▲ 13× |
| Operating profit (loss)9901 | €2.2m | €1.0m | €0.5m | €0.7m | €0.3m | €0.2m | €0.4m | ▲ 51.3% |
| Financial income75/76B | - | - | - | €0.05m | €0.006m | €0.005m | €0.006m | ▲ 15.1% |
| Recurring financial income75 | €0.002m | €0.003m | €0.006m | €0.05m | €0.006m | €0.005m | €0.006m | ▲ 15.1% |
| Other financial income752/9 | - | - | - | €0.05m | €0.006m | €0.005m | €0.006m | ▲ 15.1% |
| Financial charges65/66B | - | - | - | €0.05m | €0.04m | €0.09m | €0.1m | ▲ 42.2% |
| Recurring financial charges65 | €0.1m | €0.07m | €0.07m | €0.05m | €0.04m | €0.09m | €0.1m | ▲ 42.2% |
| Debt charges650 | €0.09m | €0.05m | €0.05m | €0.04m | €0.03m | €0.08m | €0.1m | ▲ 43.7% |
| Other financial charges652/9 | - | - | - | €0.01m | €0.007m | €0.004m | €0.005m | ▲ 11.8% |
| Profit (loss) for the period before taxes9903 | €2.1m | €1.0m | €0.4m | €0.7m | €0.3m | €0.2m | €0.2m | ▲ 55.2% |
| Income taxes67/77 | €1.2m | €0.3m | €0.1m | €0.2m | €0.1m | €0.1m | €0.07m | ▼ 43.1% |
| Taxes670/3 | - | - | - | €0.2m | €0.1m | €0.1m | €0.07m | ▼ 43.1% |
| Profit (loss) for the period9904 | €0.9m | €0.7m | €0.3m | €0.5m | €0.1m | €0.04m | €0.2m | ▲ 328% |
| Profit (loss) for the period to be appropriated9905 | €0.9m | €0.7m | €0.3m | €0.5m | €0.1m | €0.04m | €0.2m | ▲ 328% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €14.6m | €19.8m | €18.3m | €17.5m | €19.9m | €19.1m | €21.1m | ▲ 10.4% |
| Formation expenses20 | - | €0 | - | - | - | - | - | - |
| Fixed assets21/28 | €0.1m | €0.2m | €0.4m | €0.3m | €0.3m | €0.6m | €0.6m | ▼ 1.0% |
| Intangible fixed assets21 | €0.003m | €0.09m | €0.2m | €0.07m | €0.1m | €0.4m | €0.4m | ▼ 8.3% |
| Tangible fixed assets22/27 | €0.1m | €0.1m | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | ▲ 19.0% |
| Plant, machinery and equipment23 | - | - | - | €0.01m | €0.007m | €0.02m | €0.02m | ▲ 25.5% |
| Furniture and vehicles24 | - | - | - | €0.06m | €0.04m | €0.06m | €0.09m | ▲ 38.7% |
| Leasing and similar rights25 | - | - | - | €0.08m | €0.06m | €0.03m | €0.04m | ▲ 29.4% |
| Other tangible fixed assets26 | - | - | - | €0.05m | €0.06m | €0.04m | €0.03m | ▼ 28.2% |
| Financial fixed assets28 | - | - | - | - | €0.009m | €0.009m | €0.009m | = |
| Other financial fixed assets284/8 | - | - | - | - | €0.009m | €0.009m | €0.009m | = |
| Amounts receivable and cash guarantees285/8 | - | - | - | - | €0.009m | €0.009m | €0.009m | = |
| Current assets29/58 | €14.4m | €19.6m | €18.0m | €17.2m | €19.6m | €18.5m | €20.5m | ▲ 10.7% |
| Stocks and contracts in progress3 | €1.6m | €2.9m | €3.7m | €3.5m | €4.1m | €4.7m | €6.6m | ▲ 42.6% |
| Stocks30/36 | - | - | - | €3.5m | €4.1m | €4.7m | €6.6m | ▲ 42.6% |
| Goods purchased for resale34 | - | - | - | €3.5m | €4.1m | €4.7m | €6.6m | ▲ 42.6% |
| Amounts receivable within one year40/41 | €8.6m | €12.3m | €13.5m | €11.8m | €14.2m | €12.1m | €13.2m | ▲ 8.8% |
| Trade receivables40 | - | - | - | €4.3m | €4.7m | €7.1m | €4.7m | ▼ 33.9% |
| Other amounts receivable41 | - | - | - | €7.5m | €9.6m | €5.0m | €8.5m | ▲ 69.3% |
| Cash at bank and in hand54/58 | €0.01m | €0.08m | €0.8m | €2.0m | €1.2m | €1.7m | €0.6m | ▼ 62.6% |
| Deferred charges and accrued income490/1 | - | - | - | - | €0.001m | €0.001m | €0.02m | ▲ 24× |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €14.6m | €19.8m | €18.3m | €17.5m | €19.9m | €19.1m | €21.1m | ▲ 10.4% |
| Equity10/15 | €2.7m | €3.3m | €3.7m | €4.2m | €2.3m | €2.3m | €2.5m | ▲ 7.6% |
| Contributions10/11 | €1.0m | €1.0m | €1.0m | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Capital10 | - | - | - | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Issued capital100 | - | - | - | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Reserves13 | €0.2m | €0.2m | €0.2m | €0.2m | €1.3m | €1.3m | €1.5m | ▲ 13.3% |
| Non-distributable reserves130/1 | - | - | - | €0.1m | €0.1m | €0.1m | €0.1m | = |
| Legal reserve130 | - | - | - | €0.1m | €0.1m | €0.1m | €0.1m | = |
| Distributable reserves133 | - | - | - | €0.09m | €1.2m | €1.2m | €1.4m | ▲ 14.3% |
| Profit (loss) carried forward14 | €1.5m | €2.2m | €2.5m | €3.0m | - | €0 | - | - |
| Amounts payable17/49 | €11.9m | €16.5m | €14.7m | €13.4m | €17.5m | €16.7m | €18.5m | ▲ 10.8% |
| Amounts payable after more than one year17 | €1.2m | €1.0m | €0.7m | €0.3m | €0.1m | €0.05m | €0.03m | ▼ 34.2% |
| Financial debts170/4 | - | - | - | €0.3m | €0.1m | €0.05m | €0.03m | ▼ 34.2% |
| Leasing and similar obligations172 | - | - | - | €0.06m | €0.05m | €0.02m | €0.02m | ▲ 2.6% |
| Credit institutions173 | - | - | - | €0.3m | €0.06m | €0.03m | €0.01m | ▼ 57.3% |
| Amounts payable within one year42/48 | €10.7m | €15.5m | €14.0m | €13.1m | €17.4m | €16.7m | €18.5m | ▲ 10.9% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.4m | €0.2m | €0.06m | €0.04m | ▼ 27.3% |
| Financial debts43 | - | - | - | €1.5m | €1.3m | €2.0m | €2.6m | ▲ 29.2% |
| Credit institutions430/8 | - | - | - | €1.5m | €1.3m | €2.0m | €2.6m | ▲ 26.9% |
| Other loans439 | - | - | - | - | - | - | €0.05m | - |
| Trade debts44 | €7.4m | €12.6m | €12.2m | €9.6m | €12.8m | €10.5m | €11.4m | ▲ 8.4% |
| Suppliers440/4 | - | - | - | €9.6m | €12.8m | €10.5m | €11.4m | ▲ 8.4% |
| Taxes, remuneration and social security45 | - | - | - | €0.1m | €0.3m | €0.2m | €0.2m | ▼ 1.5% |
| Taxes450/3 | - | - | - | €0.02m | €0.1m | €0.05m | €0.03m | ▼ 39.0% |
| Remuneration and social security454/9 | - | - | - | €0.08m | €0.1m | €0.1m | €0.2m | ▲ 10.7% |
| Other amounts payable47/48 | - | - | - | €1.4m | €2.9m | €3.9m | €4.2m | ▲ 9.4% |
| Accrued charges and deferred income492/3 | - | - | - | €0 | €0 | €0.002m | €241 | ▼ 89.9% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.9m | €0.7m | €0.3m | €0.5m | €0.1m | €0.04m | €0.2m | ▲ 328% |
| + Depreciation and write-downs630 | €0.09m | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | ▲ 6.6% |
| Operating cash flow (approximation) | €1.0m | €0.8m | €0.4m | €0.6m | €0.3m | €0.2m | €0.3m | ▲ 96.1% |
| Investment in fixed assets (approximation) | - | -€0.2m | -€0.3m | -€0.03m | -€0.1m | -€0.4m | -€0.1m | ▲ 73.1% |
| Change in cash | - | €0.06m | €0.8m | €1.2m | -€0.8m | €0.5m | -€1.1m | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 40 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | full format | 23-06-2025 | 2025-00183981 |
| 31-12-2023 | full format | 31-07-2024 | 2024-00313952 |
| 31-12-2022 | full format | 11-07-2023 | 2023-00230650 |
| 31-12-2021 | full format | 22-06-2022 | 2022-20086627 |
| 31-12-2020 | full format | 24-06-2021 | 2021-24300545 |
| 31-12-2019 | full format | 16-07-2020 | 2020-31900034 |
| 31-12-2018 | full format | 11-07-2019 | 2019-31900384 |
| 31-12-2017 | full format | 19-07-2018 | 2018-35900463 |
| 31-12-2016 | full format | 09-10-2017 | 2017-66800010 |
| 31-12-2015 | full format | 04-07-2016 | 2016-28000277 |
Similar companies · same sector, comparable size
KERCKAERT & LABOROR
BE 0403.030.743
Lokeren · equity €2,518,108
AGUETTANT SA/NV
BE 0451.778.983
Brussel · equity €2,507,011
RevaTis
BE 0541.682.642
Marche-en-Famenne · equity €2,551,321
Advanced Practical Diagnostics
BE 0806.556.285
Turnhout · equity €2,501,266
BIOMEDICAL DIAGNOSTICS
BE 0479.414.976
Antwerpen · equity €2,469,502
Of the 1,866 active companies whose main activity is wholesale of pharmaceutical and medical goods (NACE 46460), figures are known for 1,124. 666 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Subsidies and aid
Flemish government
2022 to 2025 · 8 entries · €37,258 awarded · €37,258 paid| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 2 | €6,841 | €7,226 |
| 2024 | 2 | €8,527 | €8,142 |
| 2023 | 2 | €9,540 | €9,540 |
| 2022 | 2 | €12,350 | €12,350 |
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
1 director, last change in 2024
Board 1
PEETERS MATHIEU MANAGEMENT
CurrentNiet statutaire enige bestuurder · since 12-03-2024 · Legal entity · permanent representative: PEETERS Mathieu
Permanent representatives 1
PEETERS Mathieu
CurrentPermanent representative · since 12-03-2024 · for PEETERS MATHIEU MANAGEMENT
Statutory auditor 1
RSM INTERAUDIT
CurrentStatutory auditor · since 21-06-2023 · permanent representative: Kim Van Loon
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
19 of this company's 21 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
4 people since 2023, 2 in office
- Board
- Day-to-day management
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| PEETERS MATHIEU MANAGEMENT |
|
| RSM INTERAUDIT |
|
| BXI |
|
| PHARMA FORCE |
|
Owners and capital
Owners
1 ownerChain of control
- peeters mathieu management
- PHARMA BASE
Highest known parent: peeters mathieu management. The sources do not say who stands above it.
Owners 1
-
100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
Capital over the years
- 12-03-2024 Capital stated in the deed · €1,000,000 · 2,978 shares
Group and network
Part of the group
peeters mathieu management
7 companies
Group, risk and exposure
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
History
Acts, filings and financial milestones
2025
23-06
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
31-07
NBB filing
Annual accounts filed
financial year 2023 · full format
12-03
Gazette deed
Resignations: PHARMA FORCE (director) and BXI (director)Permanent representatives: PEETERS Mathieu and LEMMENS Ivo · Appointment: PEETERS MATHIEU MANAGEMENT (niet statutaire enige bestuurder) · Amendment of the articles13 facts ▸
Gazette deed
Resignations: PHARMA FORCE (director) and BXI (director)
Permanent representatives: PEETERS Mathieu and LEMMENS Ivo · Appointment: PEETERS MATHIEU MANAGEMENT (niet statutaire enige bestuurder) · Amendment of the articles13 facts ▸
- General meeting, 28-12-2023
- Amendment of the articles (2 times)
- Board rule, “huidige bestuursregeling geschrapt, Artikelen 11 en verder” (deed in Dutch)
- Capital, €1,000,000
- Director resignation, PHARMA FORCE (director)
- Director resignation, BXI (director)
- Director discharge, PHARMA FORCE (2 times)
- Director discharge, BXI
- Permanent representative, PEETERS Mathieu (2 times)
- Permanent representative, LEMMENS Ivo
- Director resignation, PHARMA FORCE (managing director)
- Director appointment, PEETERS MATHIEU MANAGEMENT (niet statutaire enige bestuurder)
- +1 further fact in this act
2023
31-12
Financial
Weakest financial yearnet €41,833 ▼71.6%
Net result drops to €41,833, the lowest in the series; recovery starts the following year.
11-07
NBB filing
Annual accounts filed
financial year 2022 · full format
21-06
Gazette deed
Appointment: RSM InterAudit (statutory auditor)Permanent representative: MATHIEU PEETERS4 facts ▸
Gazette deed
Appointment: RSM InterAudit (statutory auditor)
Permanent representative: MATHIEU PEETERS4 facts ▸
- General meeting, 19-05-2022
- Auditor appointment, RSM InterAudit (statutory auditor)
- Director in office, PHARMA FORCE (director)
- Permanent representative, MATHIEU PEETERS
2022
22-06
NBB filing
Annual accounts filed
financial year 2021 · full format
2021
24-06
NBB filing
Annual accounts filed
financial year 2020 · full format
2020
16-07
NBB filing
Annual accounts filed
financial year 2019 · full format
2019
11-07
NBB filing
Annual accounts filed
financial year 2018 · full format
2018
19-07
NBB filing
Annual accounts filed
financial year 2017 · full format
2017
09-10
NBB filing
Annual accounts filed
financial year 2016 · full format · 70 days late
2016
04-07
NBB filing
Annual accounts filed
financial year 2015 · full format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 40 annual accounts filed, the latest 10 are here; all 40 are under Financials.
2 of 21 deeds read
About the unread acts
Of the 21 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 19 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Register details
Identification
Legal formPublic limited company
Founded10-10-1990
Financial year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
47730Retail sale of pharmaceutical products
E-invoicing
Reachable via Peppol
Peppol ID
0208:0441943282
Also
9925:BE0441943282
Registered
24-06-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Recognitions · licences · registrations
Food safety, FASFC
1 siteGenkunit no. 2.246.434.975
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
Location & real-estate footprint
Registered office, Genk · 3 establishment units since 2015
Ground area
3.4 ha
Building footprint
2,803 m²
Building volume
18,967 m³
Parcel 71302A0002/00K033, Flanders · tallest building 7.6 m. Linked by address, not a title deed.
5
companies at this address
See who is registered here
3 establishment units
Pharma Base
since 2015unit no. 2.246.434.975
Pharma Base 2
since 2024unit no. 2.361.766.193
Pharma Base 3
since 2024unit no. 2.369.271.025
1 parcel
Flanders
1
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 71302A0002/00K033 | Flanders | 3.4 ha | 1 · 2,803 m² | 7.6 m · 2 |
How the parcels are linked
Good to know
The parcel matches the address exactly.
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “De oprichting, de handel onder elke vorm, de aankoop, de verkoop, de import, hieronder begrepen de import parallel aan de export, de groot-…” (deed in Dutch)
6 activities (deed in Dutch)
- De oprichting, de handel onder elke vorm, de aankoop, de verkoop, de import, hieronder begrepen de import parallel aan de export, de groot- en kleinhandel in farmaceutische en para farmaceutische producten, kruiden,cosmetica, parfumerie, drogisterijartikelen verbandartikelen, kruidengeneeskunde, toiletartikelen, dieetproducten, reinigingsproducten, compounding van aliopatische en homeopatische geneesmiddelen
- Activiteiten die verband houden met gezondheid individuele, klinische, medische, biologische, chemische en toxicologische analyses
- De import en export van diverse producten
- Zich borg of garant stellen ten aanzien van derden onder de vorm van een hypothecaire aanwending van haar onroerende goederen, haar roerende goederen bezwaren, en in het algemeen, om het even welke persoonlijke of zakelijke zekerheden stellen
- Alle daden van beheer, alle commerciële, productieve, financiële, industriële, burgerlijke, roerende en onroerende handelingen stellen, die rechtstreeks of onrechtstreeks, verband houden met het voorwerp van de vennootschap, of de handelingen die van die aard zijn om de realisatie van het voorwerp te vergemakkelijken, te helpen of garanderen, zowel in België als in het buitenland
- Zich door middel van inbreng, fusie, inschrijving of op alle andere wijzen interesseren in alle ondernemingen en vennootschappen, waarvan het maatschappelijk voorwerp hetzelfde, gelijkaardig, aanverwant of enkel nuttig zou zijn voor de verwezenlijking van haar voorwerp, zowel in België als in het buitenland
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Pharma Base
- Legal form clauseThe legal form, such as BV, NV or CV, which decides which company-law rules apply.
- “Naamioze vennootschap” (deed in Dutch)
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest, zowel in België als in het buitenland” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Stem van degene die vergadering voorzit doorslaggevend, raad van bestuur” (deed in Dutch)“Geheel van bestuursbevoegdheden, enige bestuurder / Raad van Bestuur” (deed in Dutch)2 more provisions on this in the deed
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Op naam, register van aandelen op naam” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Second Saturday of June at 20:00
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Artikel 33, ontbinding om welke reden en op welk ogenblik ook” (deed in Dutch)